hematopoiet
stem
cell
transplant
hsct
recipi
increas
risk
respiratori
viral
infect
associ
complic
recent
avail
multiplex
pcr
assay
rapidli
detect
varieti
respiratori
viral
pathogen
opportun
exist
better
understand
epidemiolog
clinic
impact
differ
respiratori
virus
patient
popul
although
impact
influenza
rhinoviru
respiratori
syncyti
viru
rsv
parainfluenza
well
character
hsct
recipi
littl
known
epidemiolog
clinic
signific
human
coronaviru
hcov
infect
vulner
patient
four
common
hcov
serotyp
four
strain
commonli
caus
classic
common
cold
infecti
symptom
immunocompet
individu
hsct
recipi
howev
incid
posttranspl
infect
symptomatolog
risk
risk
factor
progress
lower
respiratori
tract
infect
lrti
respiratori
failur
larg
unknown
furthermor
clinic
microbiolog
risk
factor
clinic
deterior
popul
also
unknown
inform
would
assist
clinician
identifi
hsct
recipi
hcov
infect
highest
risk
clinic
deterior
thu
warrant
closer
monitor
furthermor
data
would
inform
optim
design
futur
clinic
trial
novel
antihcov
therapi
therefor
conduct
retrospect
observ
cohort
studi
hsct
recipi
institut
infect
hcov
report
incid
epidemiolog
outcom
patient
well
risk
factor
associ
progress
proven
probabl
lrti
hsct
recipi
newyork
presbyterian
hospitalweil
cornel
medic
center
new
respiratori
symptom
nasopharyng
np
swab
collect
part
routin
clinic
care
provid
routin
swab
asymptomat
patient
patient
fever
absenc
respiratori
symptom
np
swab
test
use
respiratori
panel
biofir
diagnost
llc
salt
lake
citi
ut
usa
multiplex
pcr
assay
rapidli
detect
respiratori
virus
includ
four
main
coronaviru
serotyp
retrospect
identifi
respiratori
viral
infect
occur
patient
transplant
may
juli
calcul
cumul
incid
posttranspl
hcov
infect
cohort
compar
respiratori
virus
evalu
clinic
present
rate
risk
factor
progress
lrti
durat
viral
shed
patient
infect
hcov
first
posttranspl
episod
hcov
infect
evalu
demograph
clinic
data
collect
retrospect
patient
cohort
use
institut
electron
medic
record
hsct
databas
studi
approv
institut
review
board
weill
cornel
medicin
irb
uri
defin
exhibit
least
one
follow
symptom
cough
coryza
sore
throat
short
breath
combin
clinician
judgment
aforement
symptom
indic
respiratori
tract
infect
posit
identif
hcov
np
swab
probabl
lrti
defin
symptom
patholog
sputum
product
hypoxia
set
new
pulmonari
infiltr
radiograph
ct
scan
proven
lrti
defin
criteria
probabl
lrti
met
addit
detect
hcov
bronchoalveolar
lavag
bal
fluid
definit
consist
guidelin
diagnosi
respiratori
viru
infect
patient
leukemia
hsct
recipi
well
definit
use
prior
studi
hcov
infect
hsct
recipi
respiratori
failur
defin
need
mechan
ventil
within
day
isol
viru
respiratori
failur
list
primari
caus
death
within
day
viru
detect
persist
viral
shed
defin
persist
hcov
detect
np
swab
day
initi
diagnosi
allow
one
neg
sampl
week
two
consecut
posit
sampl
total
durat
viral
shed
calcul
first
posit
final
posit
sampl
note
followup
np
swab
routin
collect
institut
unless
patient
develop
new
worsen
recurr
respiratori
symptom
statist
analys
perform
use
stata
version
statacorp
llc
colleg
station
tx
evalu
factor
associ
develop
proven
probabl
lrti
univari
analysi
use
chisquar
fisher
exact
test
appropri
compar
categor
variabl
wilcoxon
ranksum
test
compar
continu
variabl
consid
p
valu
signific
variabl
p
valu
initi
enter
multivari
logist
regress
model
backward
stepwis
select
process
appli
variabl
p
remain
final
model
similar
univari
multivari
analys
also
perform
identifi
factor
associ
prolong
viral
shed
patient
underw
hsct
may
june
posttranspl
hcov
infect
median
followup
period
day
hcov
fourth
common
respiratori
viral
infect
popul
common
adenoviru
human
metapneumoviru
rsv
less
common
rhinovirusenteroviru
parainfluenza
influenza
fig
coronaviru
common
hcov
strain
detect
follow
fig
tabl
eight
patient
infect
two
strain
hcov
patient
patient
patient
patient
figur
reflect
season
hcov
infect
studi
popul
incid
hcov
infect
highest
month
decemb
march
serotyp
preval
season
serotyp
alter
significantli
studi
period
tabl
outlin
baselin
characterist
patient
posttranspl
hcov
infect
fiftytwo
patient
femal
median
age
infect
onset
year
acut
myeloid
leukemia
aml
common
hematolog
malign
median
time
transplant
hcov
infect
day
interquartil
rang
iqr
thirtyon
take
corticosteroid
time
hcov
infect
thirtyf
patient
coinfect
anoth
respiratori
pathogen
bacteremia
addit
patient
neutropen
lymphopen
inpati
time
diagnosi
cough
rhinorrhea
common
present
symptom
occur
patient
respect
tabl
thirtytwo
patient
fever
present
dyspnea
hypox
clinic
featur
hcov
infect
time
present
significantli
vari
among
serotyp
thirtyfour
patient
develop
proven
probabl
lrti
within
day
diagnosi
hcov
infect
eleven
patient
lrti
symptom
underw
bronchoscopi
patient
detect
hcov
bal
therefor
consid
proven
lrti
five
patient
copathogen
detect
bal
figur
b
demonstr
repres
comput
tomographi
ct
find
patient
proven
hcov
lrti
without
respiratori
copathogen
fifteen
patient
probabl
lrti
harbor
respiratori
copathogen
detect
np
swab
fig
ten
patient
requir
intub
mechan
ventil
within
day
diagnosi
infect
overal
mortal
rate
mortal
rate
thirtyf
patient
harbor
respiratori
copathogen
progress
proven
probabl
lrti
p
subgroup
analysi
respiratori
coinfect
patient
proven
probabl
lrti
significantli
associ
respiratori
failur
p
mortal
p
mortal
p
prolong
hcov
shed
p
tabl
illustr
clinic
laboratori
featur
associ
proven
probabl
lrti
patient
infect
hcov
univari
analysi
follow
variabl
associ
proven
probabl
lrti
age
year
inpati
statu
gvhd
corticosteroid
use
serum
albumin
gdl
multivari
analysi
follow
variabl
remain
independ
associ
proven
probabl
lrti
age
adjust
odd
ratio
aor
ci
p
inpati
statu
aor
ci
p
corticosteroid
use
aor
ci
p
serum
albumin
gdl
aor
ci
p
note
infect
hcov
associ
progress
proven
probabl
lrti
univari
analysi
ci
p
howev
associ
note
multivari
analysi
ci
p
fortysix
patient
repeat
nasal
swab
within
week
initi
infect
median
durat
shed
week
rang
week
twentyseven
patient
persist
viral
shed
beyond
day
initi
infect
one
coronaviru
strain
associ
persist
shed
inpati
statu
time
infect
variabl
significantli
associ
prolong
coronaviru
shed
studi
address
poorli
understood
clinic
signific
hcov
infect
hsct
recipi
found
hcov
infect
common
hsct
occur
approxim
one
hsct
recipi
medic
center
found
older
age
corticosteroid
use
hypoalbuminemia
inpati
statu
significantli
associ
proven
probabl
lrti
addit
prolong
viral
shed
detect
patient
underw
subsequ
np
swab
awar
two
previous
publish
report
incid
hcov
infect
adult
hsct
recipi
report
analyz
fewer
patient
total
studi
nearli
hsct
recipi
symptomat
hcov
infect
occur
patient
surpass
incid
rhinovirusenteroviru
influenza
parainfluenza
infect
cumul
incid
consist
incid
report
prior
studi
hsct
recipi
serotyp
frequent
detect
popul
durat
studi
account
infect
least
common
one
serotyp
profil
similar
note
institut
wide
varieti
geograph
locat
furthermor
serotyp
demonstr
winter
season
consist
prior
report
data
regard
sever
hcov
infect
hsct
recipi
previou
report
limit
find
patient
proven
probabl
lrti
compat
find
prior
studi
high
rate
proven
probabl
lrti
patient
popul
indic
hcov
infect
may
greater
clinic
signific
sever
hsct
recipi
previous
thought
like
prior
studi
coinfect
anoth
respiratori
pathogen
common
patient
hcov
fact
patient
proven
probabl
lrti
harbor
coinfect
anoth
respiratori
pathogen
detect
np
swab
p
three
potenti
explan
find
hcov
infect
increas
suscept
infect
pathogen
coinfect
respiratori
pathogen
increas
likelihood
progress
lrti
coinfect
increas
likelihood
obtain
chest
ct
bronchoscopi
lead
detect
lrti
importantli
found
subgroup
analysi
patient
proven
probabl
lrti
coinfect
anoth
respiratori
viru
associ
respiratori
failur
death
day
death
day
indic
sever
proven
probabl
hcov
lrti
independ
coinfect
univari
analysi
none
strain
significantli
associ
proven
probabl
lrti
multivari
analysi
infect
significantli
associ
progress
probabl
proven
lrti
signific
find
unclear
may
indic
pathogen
strain
hsct
recipi
distinct
associ
found
studi
research
need
examin
relationship
found
age
presenc
gvhd
corticosteroid
use
time
hcov
diagnosi
hypoalbuminemia
albumin
gdl
inpati
statu
time
infect
significantli
associ
proven
probabl
lrti
factor
may
gener
indic
frailti
suscept
sever
infect
may
highlight
individu
close
surveil
target
treatment
intervent
futur
interestingli
underli
lung
diseas
copd
asthma
appear
associ
progress
lrti
howev
number
patient
studi
comorbid
limit
well
document
literatur
influenza
rsv
rhinoviru
parainfluenza
virus
associ
prolong
viral
shed
hsct
recipi
persist
hcov
shed
hsct
recipi
poorli
understood
test
cure
routin
perform
institut
patient
undergo
repeat
np
swab
worsen
recurr
symptom
found
patient
followup
respiratori
swab
persist
shed
viru
defin
shed
day
initi
infect
one
serotyp
significantli
associ
persist
viral
shed
consist
ogimi
et
al
observ
hsct
popul
addit
median
durat
shed
cohort
week
compar
week
describ
ogimi
et
al
milano
et
al
found
hsct
recipi
asymptomat
hcov
infect
median
durat
viral
shed
week
difficult
compar
cohort
other
report
literatur
screen
asymptomat
individu
infect
test
persist
infect
repeat
np
swab
obtain
worsen
new
respiratori
symptom
clinic
relev
prolong
viral
shed
remain
unclear
understand
risk
factor
durat
shed
implic
infect
control
highli
vulner
popul
research
need
better
understand
mechan
clinic
signific
prolong
hcov
shed
studi
limit
first
retrospect
may
captur
patient
mild
symptom
test
lead
us
underestim
incid
hcov
infect
potenti
miss
mild
case
may
also
led
us
overestim
risk
progress
lrti
howev
center
polici
collect
np
swab
assess
respiratori
viral
infect
hsct
recipi
new
respiratori
symptom
studi
period
second
patient
underw
bronchoscopi
presenc
absenc
hcov
lower
respiratori
tract
discern
patient
howev
given
pneumonia
clinic
diagnosi
reli
combin
clinic
radiograph
find
diagnos
probabl
lrti
last
test
cure
respiratori
virus
standardofcar
institut
therefor
patient
persist
symptom
recurr
symptom
followup
visit
hospit
underw
repeat
np
swab
vari
interv
thu
data
persist
hcov
shed
may
underestim
prospect
studi
need
evalu
largest
studi
date
character
hcov
infect
hsct
recipi
demonstr
hcov
infect
hsct
recipi
common
clinic
signific
nearli
onethird
patient
progress
proven
probabl
lrti
describ
factor
appear
associ
progress
lrti
defin
subpopul
hsct
recipi
may
benefit
closer
monitor
aggress
support
care
infect
hcov
furthermor
may
repres
popul
target
hcov
antivir
agent
futur
clinic
trial
prospect
studi
hcov
infect
hsct
recipi
need
delin
risk
factor
lrti
prolong
viral
shed
